MedTrace Logo

Phase II Study to Evaluate the Efficacy of AMG 317

NCT00436670 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2016-03-23

No results posted yet for this study

Summary

A Multi-center, Randomized, Placebo, Multi-Dose study to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.

Conditions

Interventions

BIOLOGICAL

AMG 317 75 mg

75 mg SC weekly injection

BIOLOGICAL

AMG 317 150 mg

150 mg SC once weekly injection

BIOLOGICAL

AMG 317 300 mg

300 mg weekly SC injection

BIOLOGICAL

Placebo

Placebo SC once weekly injection

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-09-30
Completion
2009-02-28

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436670 on ClinicalTrials.gov